-
1
-
-
84883273141
-
Treatment with novel oral anticoagulants: Indications, efficacy and risks
-
Ghanny S, Crowther M. Treatment with novel oral anticoagulants: indications, efficacy and risks. Curr Opin Hematol 2013;20:430-6.
-
(2013)
Curr Opin Hematol
, vol.20
, pp. 430-436
-
-
Ghanny, S.1
Crowther, M.2
-
2
-
-
84904727777
-
Edoxaban: An update on the new oral direct factor Xa inhibitor
-
Bounameaux H, Camm AJ. Edoxaban: an update on the new oral direct factor Xa inhibitor. Drugs 2014;74:1209-31.
-
(2014)
Drugs
, vol.74
, pp. 1209-1231
-
-
Bounameaux, H.1
Camm, A.J.2
-
3
-
-
84906354978
-
Non-Vitamin K antagonist oral anticoagulants (NOACs): Clinical evidence and therapeutic considerations
-
Saraf K, Morris P, Garg P, Sheridan P, Storey R. Non-vitamin K antagonist oral anticoagulants (NOACs): clinical evidence and therapeutic considerations. Postgrad Med J 2014;90:520-8.
-
(2014)
Postgrad Med J
, vol.90
, pp. 520-528
-
-
Saraf, K.1
Morris, P.2
Garg, P.3
Sheridan, P.4
Storey, R.5
-
4
-
-
84904260419
-
New oral anticoagulants in practice: Pharmacological and practical considerations
-
Wang Y, Bajorek B. New oral anticoagulants in practice: pharmacological and practical considerations. Am J Cardiovasc Drugs 2014;14:175-89.
-
(2014)
Am J Cardiovasc Drugs
, vol.14
, pp. 175-189
-
-
Wang, Y.1
Bajorek, B.2
-
5
-
-
84905977363
-
Evolving use of new oral anticoagulants for treatment of venous thromboembolism
-
Yeh CH, Gross PL, Weitz JI. Evolving use of new oral anticoagulants for treatment of venous thromboembolism. Blood 2014;124:1020-8.
-
(2014)
Blood
, vol.124
, pp. 1020-1028
-
-
Yeh, C.H.1
Gross, P.L.2
Weitz, J.I.3
-
6
-
-
84922394366
-
Laboratory measurement of the anticoagulant activity of the non-Vitamin K oral anticoagulants
-
Cuker A, Siegal DM, Crowther MA, Garcia DA. Laboratory measurement of the anticoagulant activity of the non-vitamin K oral anticoagulants. J Am Coll Cardiol 2014;64:1128-39.
-
(2014)
J Am Coll Cardiol
, vol.64
, pp. 1128-1139
-
-
Cuker, A.1
Siegal, D.M.2
Crowther, M.A.3
Garcia, D.A.4
-
7
-
-
84929998333
-
Newer clinically available antithrombotics and their antidotes
-
Levy S. Newer clinically available antithrombotics and their antidotes. J Interv Card Electrophysiol 2014;40:269-75.
-
(2014)
J Interv Card Electrophysiol
, vol.40
, pp. 269-275
-
-
Levy, S.1
-
8
-
-
84868210856
-
Effects on routine coagulation screens and assessment of anticoagulant intensity in patients taking oral dabigatran or rivaroxaban: Guidance from the British Committee for Standards in Haematology
-
Baglin T, Keeling D, Kitchen S, British Committee for Standards in Haematology. Effects on routine coagulation screens and assessment of anticoagulant intensity in patients taking oral dabigatran or rivaroxaban: guidance from the British Committee for Standards in Haematology. Br J Haematol 2012;159:427-9.
-
(2012)
Br J Haematol
, vol.159
, pp. 427-429
-
-
British Committee for Standards in Haematology1
Baglin, T.2
Keeling, D.3
Kitchen, S.4
-
9
-
-
84883238313
-
Comparison of calibrated dilute thrombin time and aPTT tests with LC-MS/MS for the therapeutic monitoring of patients treated with dabigatran etexilate
-
Douxfils J, Dogne JM, Mullier F, Chatelain B, Ronquist-Nii Y, Malmstrom RE, et al. Comparison of calibrated dilute thrombin time and aPTT tests with LC-MS/MS for the therapeutic monitoring of patients treated with dabigatran etexilate. Thromb Haemost 2013;110:543-9.
-
(2013)
Thromb Haemost
, vol.110
, pp. 543-549
-
-
Douxfils, J.1
Dogne, J.M.2
Mullier, F.3
Chatelain, B.4
Ronquist-Nii, Y.5
Malmstrom, R.E.6
-
10
-
-
84884861345
-
Comparison of calibrated chromogenic anti-Xa assay and PT tests with LC-MS/MS for the therapeutic monitoring of patients treated with rivaroxaban
-
Douxfils J, Tamigniau A, Chatelain B, Chatelain C, Wallemacq P, Dogne JM, et al. Comparison of calibrated chromogenic anti-Xa assay and PT tests with LC-MS/MS for the therapeutic monitoring of patients treated with rivaroxaban. Thromb Haemost 2013;110:723-31.
-
(2013)
Thromb Haemost
, vol.110
, pp. 723-731
-
-
Douxfils, J.1
Tamigniau, A.2
Chatelain, B.3
Chatelain, C.4
Wallemacq, P.5
Dogne, J.M.6
-
11
-
-
84880838834
-
Impact of apixaban on routine and specific coagulation assays: A practical laboratory guide
-
Douxfils J, Chatelain C, Chatelain B, Dogne JM, Mullier F. Impact of apixaban on routine and specific coagulation assays: A practical laboratory guide. Thromb Haemost 2013;110:283-94.
-
(2013)
Thromb Haemost
, vol.110
, pp. 283-294
-
-
Douxfils, J.1
Chatelain, C.2
Chatelain, B.3
Dogne, J.M.4
Mullier, F.5
-
12
-
-
84930183306
-
Measurement of the direct oral anticoagulants apixaban, dabigatran, edoxaban, and rivaroxaban in human plasma using turbulent flow liquid chromatography with high-resolution mass spectrometry
-
Gous T, Couchman L, Patel JP, Paradzai C, Arya R, Flanagan RJ. Measurement of the direct oral anticoagulants apixaban, dabigatran, edoxaban, and rivaroxaban in human plasma using turbulent flow liquid chromatography with high-resolution mass spectrometry. Ther Drug Monit 2014;36:597-605.
-
(2014)
Ther Drug Monit
, vol.36
, pp. 597-605
-
-
Gous, T.1
Couchman, L.2
Patel, J.P.3
Paradzai, C.4
Arya, R.5
Flanagan, R.J.6
-
13
-
-
84906734062
-
Simultaneous determination of rivaroxaban and dabigatran levels in human plasma by high-performance liquid chromatography-tandem mass spectrometry
-
Korostelev M, Bihan K, Ferreol L, Tissot N, Hulot JS, Funck-Brentano C, et al. Simultaneous determination of rivaroxaban and dabigatran levels in human plasma by high-performance liquid chromatography-tandem mass spectrometry. J Pharm Biomed Anal 2014;100C:230-5.
-
(2014)
J Pharm Biomed Anal
, vol.100 C
, pp. 230-235
-
-
Korostelev, M.1
Bihan, K.2
Ferreol, L.3
Tissot, N.4
Hulot, J.S.5
Funck-Brentano, C.6
-
14
-
-
84907863533
-
Determination of dabigatran, rivaroxaban and apixaban by ultra-performance liquid chromatography-tandem mass spectrometry (UPLC-MS/MS) and coagulation assays for therapy monitoring of novel direct oral anticoagulants
-
Schmitz EM, Boonen K, van den Heuvel DJ, van Dongen JL, Schellings MW, Emmen JM, et al. Determination of dabigatran, rivaroxaban and apixaban by ultra-performance liquid chromatography-tandem mass spectrometry (UPLC-MS/MS) and coagulation assays for therapy monitoring of novel direct oral anticoagulants. J Thromb Haemost 2014;12:1636-46.
-
(2014)
J Thromb Haemost
, vol.12
, pp. 1636-1646
-
-
Schmitz, E.M.1
Boonen, K.2
Van Den Heuvel, D.J.3
Van Dongen, J.L.4
Schellings, M.W.5
Emmen, J.M.6
-
15
-
-
84892141633
-
Determination of dabigatran, rivaroxaban and apixaban using UPLC-MS/MS and comparison with coagulation assays for therapy monitoring
-
Schmitz EM, van den Heuvel DJ, Boonen K, van Dongen JL, Brunsveld L, van de Kerkhof D. Determination of dabigatran, rivaroxaban and apixaban using UPLC-MS/MS and comparison with coagulation assays for therapy monitoring. Ned Tijdschr Klin Chem Labgeneesk 2013;38:142-4.
-
(2013)
Ned Tijdschr Klin Chem Labgeneesk
, vol.38
, pp. 142-144
-
-
Schmitz, E.M.1
Van Den Heuvel, D.J.2
Boonen, K.3
Van Dongen, J.L.4
Brunsveld, L.5
Van De Kerkhof, D.6
-
16
-
-
0037663202
-
Strategies for the assessment of matrix effect in quantitative bioanalytical methods based on HPLC-MS/MS
-
Matuszewski BK, Constanzer ML, Chavez-Eng CM. Strategies for the assessment of matrix effect in quantitative bioanalytical methods based on HPLC-MS/MS. Anal Chem 2003;75:3019-30.
-
(2003)
Anal Chem
, vol.75
, pp. 3019-3030
-
-
Matuszewski, B.K.1
Constanzer, M.L.2
Chavez-Eng, C.M.3
-
17
-
-
78649392445
-
Ion suppression and enhancement effects of co-eluting analytes in multi-analyte approaches: Systematic investigation using ultrahigh-performance liquid chromatography/mass spectrometry with atmospheric-pressure chemical ionization or electrospray ionization
-
Remane D, Meyer MR, Wissenbach DK, Maurer HH. Ion suppression and enhancement effects of co-eluting analytes in multi-analyte approaches: systematic investigation using ultrahigh-performance liquid chromatography/mass spectrometry with atmospheric-pressure chemical ionization or electrospray ionization. Rapid Commun Mass Spectrom 2010;24:3103-8.
-
(2010)
Rapid Commun Mass Spectrom
, vol.24
, pp. 3103-3108
-
-
Remane, D.1
Meyer, M.R.2
Wissenbach, D.K.3
Maurer, H.H.4
-
18
-
-
77949643951
-
Systematic investigation of ion suppression and enhancement effects of fourteen stable-isotope-labeled internal standards by their native analogues using atmospheric-pressure chemical ionization and electrospray ionization and the relevance for multi-analyte liquid chromatographic/mass spectrometric procedures
-
Remane D, Wissenbach DK, Meyer MR, Maurer HH. Systematic investigation of ion suppression and enhancement effects of fourteen stable-isotope-labeled internal standards by their native analogues using atmospheric-pressure chemical ionization and electrospray ionization and the relevance for multi-analyte liquid chromatographic/mass spectrometric procedures. Rapid Commun Mass Spectrom 2010;24:859-67.
-
(2010)
Rapid Commun Mass Spectrom
, vol.24
, pp. 859-867
-
-
Remane, D.1
Wissenbach, D.K.2
Meyer, M.R.3
Maurer, H.H.4
-
20
-
-
0003484310
-
-
Accessed on 26 June, 2014
-
Food and Drug Administration. U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER), Center for Veterinary Medicine (CVM). Guidance for Industry, Bioanalytical Method Validation. Available at http://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm064964.htm. 2001. Accessed on 26 June, 2014.
-
(2001)
Guidance for Industry, Bioanalytical Method Validation
-
-
-
21
-
-
84875253725
-
Rapid determination of apixaban concentration in human plasma by liquid chromatography/tandem mass spectrometry: Application to pharmacokinetic study
-
Delavenne X, Mismetti P, Basset T. Rapid determination of apixaban concentration in human plasma by liquid chromatography/tandem mass spectrometry: application to pharmacokinetic study. J Pharm Biomed Anal 2013;78-79:150-3.
-
(2013)
J Pharm Biomed Anal
, vol.78-79
, pp. 150-153
-
-
Delavenne, X.1
Mismetti, P.2
Basset, T.3
-
22
-
-
80255134514
-
UPLC MS/MS assay for routine quantification of dabigatran-A direct thrombin inhibitor-in human plasma
-
Delavenne X, Moracchini J, Laporte S, Mismetti P, Basset T. UPLC MS/MS assay for routine quantification of dabigatran-A direct thrombin inhibitor-in human plasma. J Pharm Biomed Anal 2012;58:152-6.
-
(2012)
J Pharm Biomed Anal
, vol.58
, pp. 152-156
-
-
Delavenne, X.1
Moracchini, J.2
Laporte, S.3
Mismetti, P.4
Basset, T.5
-
23
-
-
49849103069
-
Determination of rivaroxaban-A novel, oral, direct Factor Xa inhibitor-in human plasma by high-performance liquid chromatography-tandem mass spectrometry
-
Rohde G. Determination of rivaroxaban-A novel, oral, direct Factor Xa inhibitor-in human plasma by high-performance liquid chromatography-tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci 2008;872:43-50.
-
(2008)
J Chromatogr B Analyt Technol Biomed Life Sci
, vol.872
, pp. 43-50
-
-
Rohde, G.1
-
24
-
-
0026580927
-
MW/Pharm, an integrated software package for drug dosage regimen calculation and therapeutic drug monitoring
-
Proost JH, Meijer DK. MW/Pharm, an integrated software package for drug dosage regimen calculation and therapeutic drug monitoring. Comput Biol Med 1992;22:155-63.
-
(1992)
Comput Biol Med
, vol.22
, pp. 155-163
-
-
Proost, J.H.1
Meijer, D.K.2
-
25
-
-
84882909945
-
Novel oral anticoagulants: Clinical pharmacology, indications and practical considerations
-
Harder S, Graff J. Novel oral anticoagulants: clinical pharmacology, indications and practical considerations. Eur J Clin Pharmacol 2013;69:1617-33.
-
(2013)
Eur J Clin Pharmacol
, vol.69
, pp. 1617-1633
-
-
Harder, S.1
Graff, J.2
-
26
-
-
84881474743
-
Measuring the anticoagulant effects of target specific oral anticoagulants-reasons, methods and current limitations
-
Mani H, Kasper A, Lindhoff-Last E. Measuring the anticoagulant effects of target specific oral anticoagulants-reasons, methods and current limitations. J Thromb Thrombolysis 2013;36:187-94.
-
(2013)
J Thromb Thrombolysis
, vol.36
, pp. 187-194
-
-
Mani, H.1
Kasper, A.2
Lindhoff-Last, E.3
-
27
-
-
84886734099
-
Therapeutic drug monitoring for tomorrow
-
Eliasson E, Lindh JD, Malmstrom RE, Beck O, Dahl ML. Therapeutic drug monitoring for tomorrow. Eur J Clin Pharmacol 2013;69(Suppl 1):25-32.
-
(2013)
Eur J Clin Pharmacol
, vol.69
, pp. 25-32
-
-
Eliasson, E.1
Lindh, J.D.2
Malmstrom, R.E.3
Beck, O.4
Dahl, M.L.5
|